Maastricht, London, Zurich – 26.03.2025 – Partners4Access (P4A), a global leader in pharmaceutical innovation and orphan drug access, is proud to share the results of
Partners4Access, a global leader in pharmaceutical innovation and orphan drug access are proud to announce that Consultant, Olivia Johns has accepted the role of DMD
Zug, Switzerland – 13th May 2025 – Partners4Access (P4A), a global leader in market access for orphan drugs and advanced therapies, is excited to host the P4A
Partners4Access, a global leader in pharmaceutical innovation and orphan drug access are proud to announce that Pina (Josephina) Haberl has accepted the role of Chief
With these posters, Partners4Access showcases its commitment to advancing health economics and outcomes research (HEOR) in orphan drugs and ATMPs. Representing Partners4Access at ISPOR 2024
We are thrilled to announce that RarePULSE® our innovative omnichannel service has officially received registered trademark status from the Intellectual Property Office (IPO). This designation
[London, UK] Partners4Access (P4A) is proud to announce the launch of its new Digital Solutions, designed to revolutionize how pharmaceutical companies approach product launches in the rare
London, UK – Partners4Access (P4A) is excited to announce that Managing Partner Sophie Schmitz will be attending the highly anticipated Cell & Gene Meeting on
London, UK – 22nd Aug 2024 – Partners4Access (P4A), a leading global consultancy specializing in orphan drugs, cell and gene therapies, market access, is proud
